

04-18-07

IFW


1633

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT**  
(Under 37 CFR 1.97(b) or 1.97(c))Docket No.  
16778.5a.1.1

In Re Application Of: Ole Thastrup, et al.

Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/072,036	February 5, 2002	M. D. Burkhardt	22913	1633	3012

Title: A METHOD FOR EXTRACTING QUANTITATIVE INFORMATION RELATING TO AN INFLUENCE ON A CELLULAR RESPONSE

Address to:  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450**37 CFR 1.97(b)**

1. ☐ The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

**37 CFR 1.97(c)**

2. ☒ The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:

☐ the statement specified in 37 CFR 1.97(e);

OR

☒ the fee set forth in 37 CFR 1.17(p).

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT**  
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.  
16778.5a.1.1

In Re Application of: **Ole Thastrup, et al.**

Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/072,036	February 5, 2002	M. D. Burkhardt	22913	1633	3012

Title: **A METHOD FOR EXTRACTING QUANTITATIVE INFORMATION RELATING TO AN INFLUENCE ON A CELLULAR RESPONSE**



**Payment of Fee**

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☐ A check in the amount of \_\_\_\_\_ is attached.
- ☒ The Director is hereby authorized to charge and credit Deposit Account No. 23-3178 as described below.
- ☐ Charge the amount of \_\_\_\_\_
- ☒ Credit any overpayment.
- ☒ Charge any additional fee required.
- ☒ Payment by credit card.

**WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.**

**Certificate of Transmission by Facsimile\***

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fa

\_\_\_\_\_  
(Date)

\_\_\_\_\_  
Signature

\_\_\_\_\_  
Typed or Printed Name of Person Signing Certificate

**Certificate of Mailing by First Class Mail**

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on

4-17-07

\_\_\_\_\_  
(Date)

Angela J. Brimhall

\_\_\_\_\_  
Signature of Person Mailing Correspondence

Angela J. Brimhall

\_\_\_\_\_  
Typed or Printed Name of Person Mailing Certificate


**\*This certificate may only be used if paying by deposit account.**

[Signature]  
Signature

Dated: 4/17/07

11E V935549764US

CC:



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Ole Thastrup et al.

Serial No.: 10/072,036

Confirmation No.: 3012

Filed: February 5, 2002

For: A METHOD FOR EXTRACTING  
QUANTITATIVE INFORMATION RELATING  
TO AN INFLUENCE ON A CELLULAR  
RESPONSE

Examiner: M. D. Burkhart

Customer No.: 022913

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT  
UNDER 37 C.F.R. § 1.97

Mail Stop AMENDMENT  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Please find, pursuant to 37 C.F.R. § 1.98(a)(1), the enclosed Form PTO-1449 which contains a list of all patents, publications, or other items that have come to the attention of one or more of the individuals designated in 37 C.F.R. § 1.56(c). While no representation is made that any of these references may be “prior art” within the meaning of that term under 35 U.S.C. §§

102 or 103, the enclosed list of references is disclosed so as to fully comply with the duty of disclosure set forth in 37 C.F.R. § 1.56.

Moreover, while no representation is made that a specific search of office files or patent office records has been conducted or that no better art exists, the undersigned attorney of record believes that the enclosed art is the closest to the claimed invention (taken in its entirety) of which the undersigned is presently aware, and no art which is closer to the claimed invention (taken in its entirety) has been knowingly withheld.


In accordance with 37 C.F.R. § 1.98(c), all English translations within the possession, custody, control or availability of anyone designated in 37 C.F.R. § 1.56(c) of each non-English reference, if any, are also enclosed.

Since all listed references are either in the English language or are accompanied by a translation into English, no concise explanation of relevance is required under 37 C.F.R. § 1.98(a)(3).

Please credit any over payment or charge any additional fees to Deposit Account No. 23-3178 of the undersigned.

Dated this 17 day of April, 2007.

Respectfully submitted,



JONATHAN M. BENNS  
Attorney for Applicant(s)  
Registration No. 53,983  
Customer No. 022913

Applicant: Ole Thastrup et al.

Serial No.: 10/072,036


Docket No.: 16778.5a.1.1

Filing Date: February 5, 2002

Group: 1633

Confirmation No.: 3012

A METHOD FOR EXTRACTING QUANTITATIVE INFORMATION  
RELATING TO AN INFLUENCE ON A CELLULAR RESPONSE



SUPPLEMENTAL INFORMATION DISCLOSURE CITATIONS MADE BY APPLICANT

U.S. Patent Documents

Examiner Initial*	Document Number	Issue Date	Name
_____ A1.	4,508,752	04/02/85	Takei et al.
_____ A2.	4,547,393	10/15/85	Asai et al.
_____ A3.	4,567,057	01/28/86	Masuyama et al.
_____ A4.	4,874,633	10/17/89	Komatsu et al.
_____ A5.	4,923,766	05/08/90	Hosol et al.
_____ A6.	5,168,639	12/08/92	Hebels
_____ A7.	5,958,713	09/28/99	Thastrup et al.

U.S. Patent Application Publications

Examiner Initial*	Document Number	Issue Date	Name
_____ A8.	None		

Foreign Patent Documents

Examiner Initial*	Document Number	Publication Date	Country or Patent Office
_____ A9.	WO9838490	03/09/98	WIPO

Examiner:

Date Considered:

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609, draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant: Ole Thastrup et al.

Serial No.: 10/072,036

Docket No.: 16778.5a.1.1

Filing Date: February 5, 2002

Group: 1633

Confirmation No.: 3012

For: A METHOD FOR EXTRACTING QUANTITATIVE INFORMATION  
RELATING TO AN INFLUENCE ON A CELLULAR RESPONSE



_____ A10.	WO0049183	08/24/00	WIPO
_____ A11.	WO0075332	12/14/00	WIPO
_____ A12.	DE3240063	05/26/83	DE
_____ A13.	GB4101041	07/23/75	GB

Other Documents

(including author, title, pertinent pages, etc.)

Examiner

Initial\*

- \_\_\_\_\_ A14. Biondi, Richard M. et al., "Random Insertion of GFP in the cAMP-dependent Protein Kinase Regulatory Subunit from Dictyostelium Discoideum," Nucleic Acids Research, Vol. 26, No. 21, November 1, 1998, pp. 4946-4952.
- \_\_\_\_\_ A15. Cubitt A. B. et al., "Understanding, Improving, and Using Green Fluorescent Proteins," Trends In Biochemical Sciences, Vol. 20, No. 11, 1995, pp. 448-455.
- \_\_\_\_\_ A16. Macara, I.G. et al., "Real-Time Detection of Ligand-Induced Nuclear Transport Using a Glucocorticoid Receptor- Green Fluorescent Protein Fusion Construct," Molecular Biology of the Cell, Vol. 6, No. Suppl., November 1, 1995, p. 313A.
- \_\_\_\_\_ A17. Pines, J., "GFP in Mammalian Cells," Trends In Genetics, Vol. 11, No. 8, 1995, pp. 326-327.
- \_\_\_\_\_ A18. Gerdes, H. H. et al., "Green Fluorescent Protein: Applications In Cell Biology," FEBS Letters, Vol. 389, 1996, pp. 44-47.

Examiner:

Date Considered:

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609, draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant: Ole Thastrup et al.


Serial No.: 10/072,036

Docket No.: 16778.5a.1.1

Filing Date: February 5, 2002

Group: 1633

Confirmation No.: 3012

For: A METHOD FOR EXTRACTING QUANTITATIVE INFORMATION  
RELATING TO AN INFLUENCE ON A CELLULAR RESPONSE**References Cited by Applicants**

While the filing of Information Disclosure Statements is voluntary, the procedure is governed by the guidelines of Section 609 of the Manual of Patent Examining Procedure and 37 C.F.R. §§ 1.97 and 1.98. To be considered a proper Information Disclosure Statement, Form PTO-1449 shall be accompanied by a copy of each listed patent or publication or other item of information and a translation of the pertinent portions of foreign documents (if an existing translation is readily available to the applicant), an explanation of relevance of each reference not in the English language, and should be submitted in a timely manner as set out in MPEP Sec. 609.

Examiners will consider all citations submitted in conformance with 37 C.F.R. § 1.98 and MPEP Sec. 609 and place their initials adjacent the citations in the spaces provided on this form. Examiners will also initial citations not in conformance with the guidelines which may have been considered. A reference may be considered by the Examiner for any reason whether or not the citation is in full conformance with the guidelines. A line will be drawn through a citation if it is not in conformance with the guidelines AND has not been considered. A copy of the submitted form, as reviewed by the Examiner, will be returned to the applicant with the next communication. The original of the form will be entered into the application file.

Each citation initialed by the Examiner will be printed on the issued patent in the same manner as references cited by the Examiner on Form PTO-892.

The reference designations "A1," "A2," etc. (referring to Applicant's reference 1, Applicant's reference 2, etc.) will be used by the Examiner in the same manner as Examiner's reference designations "A," "B," "C," etc. on Office Action Form PTO-1142.

W:\16778\SA.1.1\AJB0000000478V001.doc

Examiner:

Date Considered:

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609, draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.